New medical research group

A new Nvidia research group has begun operating in Israel, using artificial intelligence to accelerate medical and scientific breakthroughs. The Applied AI Architecture group is recruiting in Israel and will work on AI applications ranging from genomics and medicine discovery to new materials.

Genetic discovery explains rare hearing loss

Researchers from Bethlehem University, Seattle University, and Tel Aviv University have uncovered how the FMN1 gene maintains the inner ear’s structural integrity. Four Arab children had two copies of an FMN1 variant, generating silver-gray hair and moderate hearing loss.

The right dose

Israel’s DreaMed Diabetes (see previously) has received FDA approval for its MODI system. MODI uses glucose-monitoring data to automatically optimize insulin dosing for people with type 2 diabetes across both basal-only (steady regulation) and bolus (booster) insulin regimens.

Ketamine for pain relief only

A new study by Tel Aviv University scientists reveals that ketamine's pain-relieving effects and its influence on consciousness involve separate brain mechanisms, opening possibilities for reducing psychological side effects.

Guardian proteins protect tumors

Scientists at Israel’s Ben Gurion University have identified two guardian proteins that allow cancer cells to stay alive after chemotherapy. DNAJB12 and DNAJB14 sit on the wall of a cell’s protein factory – the endoplasmic reticulum. Chemotherapy releases them, to attack anti-cancer enzymes.  

Breast cancer survival rates exceed 85%

Since 2013, the risk of invasive breast cancer among Israeli Jewish women has declined by an average of 1.6% annually. Israel ranks 33rd among 186 countries for breast cancer incidence but only 125th for mortality. Early detection and genetic screening are key reasons.

Successful treatment for bladder cancer

Shaare Zedek Medical Center in Jerusalem is treating high-risk non-muscle invasive bladder cancer (NMIBC) patients with NDV-01 biodegradable polymer gel that releases chemo continuously over 14 days. 95% of patients achieved a complete response, with 76% disease-free after one year.

Long-lasting schizophrenia treatment

Israel’s Teva has received FDA approval for Weltruza, a monthly injection for adults with schizophrenia. The long-acting injectable contains the antipsychotic olanzapine to help patients who have difficulty taking daily medications. (But not in UK pharmacies.)

Gene therapy for baby with epilepsy

In a medical world first, doctors at Israel’s Schneider Children’s Medical Center in Petah Tikva have delivered gene therapy into the brain of an eight-month-old baby suffering from a rare, life-threatening form of genetic epilepsy. They injected healthy copies of the faulty WWOX gene.

Breakthrough may restore hearing

Tel Aviv University researchers have discovered that irreversible hearing loss caused by damage to inner ear hair cells, may be reversed by converting nearby “transdifferentiating Deiters’ cells (tDCs) from supporting cells to hair cells. Expanding this to other cells could restore hearing.